Abstract

BackgroundThe dysregulation of transforming growth factor-β (TGF-β) signaling plays a crucial role in ovarian carcinogenesis and in maintaining cancer stem cell properties. Classified as a member of the ATP-binding cassette (ABC) family, ABCA1 was previously identified by methylated DNA immunoprecipitation microarray (mDIP-Chip) to be methylated in ovarian cancer cell lines, A2780 and CP70. By microarray, it was also found to be upregulated in immortalized ovarian surface epithelial (IOSE) cells following TGF-β treatment. Thus, we hypothesized that ABCA1 may be involved in ovarian cancer and its initiation.ResultsWe first compared the expression level of ABCA1 in IOSE cells and a panel of ovarian cancer cell lines and found that ABCA1 was expressed in HeyC2, SKOV3, MCP3, and MCP2 ovarian cancer cell lines but downregulated in A2780 and CP70 ovarian cancer cell lines. The reduced expression of ABCA1 in A2780 and CP70 cells was associated with promoter hypermethylation, as demonstrated by bisulfite pyro-sequencing. We also found that knockdown of ABCA1 increased the cholesterol level and promoted cell growth in vitro and in vivo. Further analysis of ABCA1 methylation in 76 ovarian cancer patient samples demonstrated that patients with higher ABCA1 methylation are associated with high stage (P = 0.0131) and grade (P = 0.0137). Kaplan-Meier analysis also found that patients with higher levels of methylation of ABCA1 have shorter overall survival (P = 0.019). Furthermore, tissue microarray using 55 ovarian cancer patient samples revealed that patients with a lower level of ABCA1 expression are associated with shorter progress-free survival (P = 0.038).ConclusionsABCA1 may be a tumor suppressor and is hypermethylated in a subset of ovarian cancer patients. Hypermethylation of ABCA1 is associated with poor prognosis in these patients.Electronic supplementary materialThe online version of this article (doi:10.1186/s13148-014-0036-2) contains supplementary material, which is available to authorized users.

Highlights

  • The dysregulation of transforming growth factor-β (TGF-β) signaling plays a crucial role in ovarian carcinogenesis and in maintaining cancer stem cell properties

  • ABCA1 is epigenetically silenced in ovarian cancer cells Our previous studies demonstrated that novel TGF-β targets, FBXO32 and RunX1T1, are epigenetically silenced by promoter hypermethylation in ovarian cancer [10,11]

  • To identify additional genes regulated by TGF-β that exhibited promoter hypermethylation in ovarian cancer, we performed mDIP-Chip in immortalized ovarian surface epithelial (IOSE) cells and a panel of ovarian cancer cell lines [13]

Read more

Summary

Introduction

The dysregulation of transforming growth factor-β (TGF-β) signaling plays a crucial role in ovarian carcinogenesis and in maintaining cancer stem cell properties. It was found to be upregulated in immortalized ovarian surface epithelial (IOSE) cells following TGF-β treatment. The transforming growth factor-β (TGF-β) signaling pathway plays an important role in the regulation of ovarian growth [3]. Chou et al Clinical Epigenetics (2015) 7:1 rupture, followed by proliferation-mediated repair This growth is inhibited by TGF-β, which plays a key role in preventing overproliferation of OSE cells [4]. In this regard, the dysregulation of TGF-β signaling may be an early step in the development of epithelial ovarian cancer. This is in agreement with the observation that resistance to TGF-β signaling is commonly seen in ovarian cancer, suggesting that reduced responsiveness to TGF-β is a key event in ovarian cancer [5]

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call